BioHealth Innovation, Inc. (BHI), a new regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in the Central Maryland region, announced today the appointment of its Board of Directors, including Scott Carmer, MedImmune Executive Vice President of Commercial Operations, as Chairman.
"The State of Maryland is known as one of the most well-established biohealth research regions in the world," said Richard Bendis, BHI Interim CEO, "what we need is an integrated commercialization ecosystem to turn such research assets into economic success by fostering the next generation of 'MedImmunes' here. We are grateful for MedImmune's strong support and Scott's leadership to help us advance early-stage research from laboratories to market with the founding of new start-up companies."